Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin
- PMID: 18280438
- DOI: 10.1016/j.jdiacomp.2007.07.002
Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin
Abstract
Purpose: This article aims to study the effects of ruboxistaurin (RBX) on skin microvascular blood flow (SkBF) and evaluate the relationship between endothelial and neural control of SkBF in patients with diabetic peripheral neuropathy (DPN).
Methods: We studied 11 placebo- and 9 RBX (32 mg/day)-treated patients who participated in a 1-year, double-masked, randomized, Phase 3 study of RBX for treatment of DPN sensory symptoms. Patients had type 1 or type 2 diabetes, a detectable sural sensory nerve action potential, and Neuropathy Total Symptom Score-6 (NTSS-6) >6 points. SkBF was measured by laser Doppler velocimetry, combined with iontophoresis of acetylcholine and sodium nitroprusside, at baseline, 3 months, and 1 year. Sensory symptoms and electrophysiology were also evaluated during the study. The relationship between endothelial and neural control of SkBF at baseline was assessed using linear regression.
Results: No significant differences (RBX vs. placebo) were demonstrable for post-iontophoresis SkBF [fold increase from basal state (1 year): endothelium-dependent, 3.6 vs. 8.6; endothelium-independent, 3.7 vs. 2.0; C fiber-mediated, 1.7 vs. 2.0; P>.05] or sensory symptoms [NTSS-6 total score (1 year): 7.7 vs. 6.0 points; P=.4]. There were also no significant between-group differences in nerve conduction parameters, except for placebo peroneal nerve conduction velocity, which demonstrated a statistically significant improvement of unknown clinical importance (Z=2.1; P=.034). At baseline, C fiber-mediated vasodilatation correlated well with endothelium-dependent vasodilation (r=.7, P<.01) but not with endothelium-independent vasodilatation (r=-.1, P=.7).
Conclusions: RBX demonstrated no effect on SkBF or sensory symptoms after 1 year in this cohort. The correlation between C fiber-mediated and endothelium-dependent SkBF at baseline suggests that improving endothelial function could affect the microcirculation not only locally but also via the neurovascular arcade.
Similar articles
-
A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.Diabetes Care. 2007 Apr;30(4):896-902. doi: 10.2337/dc06-1699. Diabetes Care. 2007. PMID: 17392551 Clinical Trial.
-
Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.Clin Ther. 2005 Aug;27(8):1164-80. doi: 10.1016/j.clinthera.2005.08.001. Clin Ther. 2005. PMID: 16199243 Clinical Trial.
-
Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.Invest Ophthalmol Vis Sci. 2006 Jan;47(1):86-92. doi: 10.1167/iovs.05-0757. Invest Ophthalmol Vis Sci. 2006. PMID: 16384948 Clinical Trial.
-
Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.Ann Pharmacother. 2005 Oct;39(10):1693-9. doi: 10.1345/aph.1E572. Epub 2005 Sep 13. Ann Pharmacother. 2005. PMID: 16160002 Review.
-
[Protein kinase C beta-Inhibitor ruboxistaurin].Med Monatsschr Pharm. 2005 Aug;28(8):292-3. Med Monatsschr Pharm. 2005. PMID: 16128544 Review. German. No abstract available.
Cited by
-
Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?Diagnostics (Basel). 2022 Mar 17;12(3):731. doi: 10.3390/diagnostics12030731. Diagnostics (Basel). 2022. PMID: 35328284 Free PMC article. Review.
-
Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials.Diabetes Metab J. 2013 Oct;37(5):375-84. doi: 10.4093/dmj.2013.37.5.375. Epub 2013 Oct 17. Diabetes Metab J. 2013. PMID: 24199167 Free PMC article.
-
Evolving pandemic diabetic nephropathy.Rambam Maimonides Med J. 2010 Jul 2;1(1):e0005. doi: 10.5041/RMMJ.10005. Print 2010 Jul. Rambam Maimonides Med J. 2010. PMID: 23908777 Free PMC article.
-
Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus.Am J Physiol Regul Integr Comp Physiol. 2012 Oct 1;303(7):R710-8. doi: 10.1152/ajpregu.00286.2012. Epub 2012 Aug 1. Am J Physiol Regul Integr Comp Physiol. 2012. PMID: 22855276 Free PMC article. Clinical Trial.
-
Role for protein kinase C delta in the functional activity of human UGT1A6: implications for drug-drug interactions between PKC inhibitors and UGT1A6.Xenobiotica. 2010 May;40(5):306-18. doi: 10.3109/00498251003596817. Xenobiotica. 2010. PMID: 20196639 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical